| Literature DB >> 28926969 |
Tadeu Uggere de Andrade1, Girlandia Alexandre Brasil2, Denise Coutinho Endringer3, Flávio Rogério da Nóbrega4, Damião Pergentino de Sousa5.
Abstract
Cardiovascular diseases are a leading cause of death in developed and developing countries and decrease the quality of life, which has enormous social and economic consequences for the population. Recent studies on essential oils have attracted attention and encouraged continued research of this group of natural products because of their effects on the cardiovascular system. The pharmacological data indicate a therapeutic potential for essential oils for use in the treatment of cardiovascular diseases. Therefore, this review reports the current studies of essential oils chemical constituents with cardiovascular activity, including a description of their mechanisms of action.Entities:
Keywords: heart; hypertension; monoterpene; natural products; phenylpropanoid; sesquiterpene; smooth muscle; spasmolytic; vasorelaxation
Mesh:
Substances:
Year: 2017 PMID: 28926969 PMCID: PMC6151533 DOI: 10.3390/molecules22091539
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
In vitro cardiovascular effects of the chemical constituents of essential oils.
| Compound | Assay | Concentration | Effects | Reference |
|---|---|---|---|---|
| Rat smooth muscle from vascular and non-vascular | 1–1000 μmol/L | Relaxation by acting in Ca2+ voltagem-dependent channel | [ | |
| Porcine splenic artery and coronary artery | 3, 10 and 30 μM | Vasodilatation by inhibiting calcium influx | [ | |
| Rat thoracic aorta and mesenteric ring | 1–1000 μmol/L | Vasorelaxation by acting in Ca2+ voltagem-dependent channel | [ | |
| Human internal mammary artery | Phytotherapic preparation enriched with borneol (1 mg/mL) | Vasorelaxation with and without endothelium | [ | |
| Rat thoracic aorta artery | 10−9 to 3 × 10−4 M | Vasorelaxant effect, probably by potassium channels activation, reduction in calcium influx and inhibition of calcium mobilization from intracellular stores | [ | |
| Rat thoracic aorta artery | 1, 10 and 100 μmol L−1 | Vasorelaxant effect via inhibition of ROS and stimulation of NOS | [ | |
| Rat Cerebral and cerebellar pial Arteries | 10 and 30 μM | Vasodilatation by increase on calcium influx, by activating TRPV3 channel | [ | |
| Rat superior mesenteric artery | 10−8 to 3 × 10−4 M | Vasorelaxation by inhibition calcium influx through the L-type Cav, ROC and SOC channels | [ | |
| Atria isolates | 10 μM and 100 μM | Negative inotropic and chronotropic effect | [ | |
| Rat thoracic aorta | 100 μM | Vasorelaxation by blocking calcium influx through VDDC | [ | |
| Rat thoracic aorta and trachea of guinea pigs | 10−6 to 3 × 10−4 M | Vasorelaxant effect | [ | |
| Rat thoracic aorta | 10−7, 10−6, 10−5, and 10−4 g/mL | Vasodilatory effect by inhibiting both Ca2+ influx and Ca2+ release | [ | |
| Porcine coronary artery | 32–320 μM | Vasorelaxation by inhibiting Ca2+ sensitivity and Ca2+ influx | [ | |
| Ventricular cardiomyocytes and vascular smooth muscle cells | 0.01–1000 μM | Vasorelaxing action by inhibiting L-type Ca2+ channels and possible participation of TRPA1 | [ | |
| Rat aorta artery and Human | 10 μM | Prevents endothelial dysfunction by attenuating ROS generation and | ||
| umbilical vein endothelial cells (HUVECs) | preserving nitric oxide levels and Nrf2 activation and the up-regulation of downstream target proteins | [ | ||
| Rat thoracic Aorta | 0.1 mM, 0.2 mM, 0.4 mM, 1 mM, and 2 mM | Vasodilation via the NO–cGMP-PKG pathway, which stimulates Ca2+-activated K+ channels | [ | |
| Rat thoracic aorta artery | 0.2 mM, 0.4 mM, 0.6 mM, 1 mM or 1.5 mM | Vasodilation by activation of K+ channels and inhibition of Rho-kinase, which inhibit Ca2+ sensitization via the NO-cGMP-PKG pathway | [ | |
| Rat thoracic Aorta artery | 0.6 to 6 mM | Vasorelaxation by reduced the calcium influx by the blockade of voltage dependent L-type Ca2+ channels | [ | |
| Rat atria Muscle | 1, 3, 5, 7, and 10 mM | Increase in resting tension by cooperative activation of cardiac thin filaments by strongly attached cross-bridges (rigor state) | [ | |
| Rat atria Muscle | 1, 3, 5, 7, and 10 mM | Increase in resting tension by cooperative activation of cardiac thin filaments by strongly attached cross-bridges (rigor state) | ||
| Rat thoracic aorta artery | 1, 10 and 100 μmol L−1 | Vasorelaxant effect via inhibition of ROS and stimulation of NOS | [ | |
| Rat thoracic aorta artery | 100 μM | Vasorelaxation by inhibiting ROS and elevating NO | [ | |
| Rat cerebral artery | 100 μM | Vasorelaxation by inhibiting voltage-dependent Ca2+ | [ | |
| Porcine splenic artery and coronary artery | 3, 10 and 30 μM | Vasodilatation by inhibiting calcium influx | [ | |
| Rat thoracic aorta and trachea of guinea pigs | 10−6 to 3 × 10−4 M | Vasorelaxant effect | [ | |
| Rat thoracic aorta | 500 μM | Vasorelaxation by activating sGC and K+ channels and by inhibiting Ca2+ influx | [ | |
| Rat thoracic aorta | 100 μM | Vasorelaxation by blocking voltage dependent calcium channel (VDCC) and elevating NO | [ | |
| The mouse vascular smooth muscle cell line MOVAS-1 (MOVAS) and human umbilical vein endothelial cell line EA.hy926 (EA) | 0.01% | Increase the intracellular K+ levels | [ | |
| Rat aorta, mesenteric and coronary arteries | 0.01-1 mM | Vasorelaxation through inhibiting Ca2+ influx via nifedipine-sensitive Ca2+ channels in vascular smooth muscle | [ | |
| Human umbilical vein endothelial cells (HUVECs) | 20–50 μg/mL | Anti-angiogenic activities by increase of maintaining cell cycle on G0–G1 phase, and promoting apoptosis | [ | |
| Rat superior mesenteric artery | 10−7 to 3 × 10−3 M | Vasorelaxation through activation of BKCa channels and by the inhibition of Ca2+ entry through L-type Ca2+ channels | [ |
In vivo cardiovascular effects of the chemical constituents of essential oils.
| Compound | Model | Dose | Effects | Reference |
|---|---|---|---|---|
| Spontaneously hypertensive rats (SHR) | 1–10 mg/kg | Promotes bradycardic and hypotensive responses after in bolus application. The mechanism suggested is by cholinergic and vagal reflex activation | [ | |
| DOCA-salt hypertensive rats | 2–16 mg/kg/day | Decrease of blood pressure dose and time dependent | [ | |
| Transient cerebral ischemia by intraluminal middle cerebral artery occlusion (MCAO) | 0.8 mg/kg | Decrease of pro-inflammatory markers and infarct area. Antioxidant proprieties of borneol were associated with these effects | [ | |
| Wistar rats | 1–20 mg/kg | Hypotension and bradycardic effects associated with a decrease in heart rate, in a dose-dependent manner | [ | |
| Isoproterenol model of myocardial ischemia | 22.5, 45 and 90 mg/kg | Decrease of cardiac injury and pro-inflammatory cytokines after per-treatment (14 days), additionally an increase of NO and SOD levels of heart tissue | [ | |
| Isoproterenol model of myocardial ischemia | 37.5, 75 and 150 mg/kg | Decrease of biochemical markers of myocardial infarct and increase of NO levels. Indicating antioxidant proprieties of CD | [ | |
| 5, 10, 20, and 40 mg/kg in bolus and 200 mg/kg orally | In bolus promotes hypotensive and bradycardic effects of normotensive rats. Treatment of
| [ | ||
| Normotensive rat | 1–20 mg/kg | They evaluate the essential oil of Rosewood enriched with linalool.
| [ | |
| 25–100 mg/kg/day | Cardioprotective effect by induced hypotension and antioxidant potential by restoring antioxidant enzyme activities (catalase and glutathione peroxidase) | [ | ||
| Airway inflammation by acute exposure to diesel exhaust particles (DEP) | 0.01–0.1 mg/mL | Pre-treatment with thymoquinone prevents the worse effects promoted by DEP such as leukocytosis, increase of IL-6 and decrease of SOD plasma activity. The platelet numbers and prothrombotic events were also decreased | [ | |
| Isoproterenol model of myocardial ischemia | 12.5–50 mg/kg | Antioxidant and Cardioprotective effects by decrease of LDH levels and TBARS activity. The SOD activity was increased to almost normal levels. The GSH/GSSG ratio decreased gradually and returned to near normal levels with corresponding increases in the dose | [ | |
| Abdominal aorta ischemia followed by reperfusion (I/R) | 20 mg/kg | Reduction of oxidative stress determined by Total Oxidant Status and Oxidative Stress Index in blood samples. Decreased of histopathologic injury in in lung, renal, and heart tissues | [ | |
| Systolic blood pressure measured in rats | 0.1 mg/kg | Antihypertensive activity associated with the regulation of nitric oxide and oxidative stress in rats chronically exposed to nicotine | [ |